FDA approval of firm's NIRoyal coronary stent mounted on a Monorail delivery system via premarket approval application supplement allows for release of first gold-coated stent in the U.S., the company reports May 25. Available in lengths 9, 12, 15, 18, 25 and 31 mm and diameters of 2.0-4.0 mm in 0.5 mm increments, the device provides enhanced visibility over currently available stents, the firm claims. The product, which is said to have been delayed in gaining final agency go-ahead, is indicated for improving coronary luminal diameter in patients with symptomatic ischemic disease due to discrete (de novo) lesions in native coronary arteries (length equal to or less than 25mm) with a reference vessel diameter of 3.0 - 4.0 mm; treatment of abrupt or threatened closure in patients with failed interventional therapy in lesions with reference diameters in the range of 2.5-4.0 mm; and patients with symptomatic heart disease due to lesions in saphenous vein bypass grafts with lesion length equal to or less than 30 mm and reference diameter in the range of 3.0-4.0 mm. The firm's gold-coated NIRoyal Elite stent, which includes the SOX securement system, is pending FDA approval
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.
Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.
In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul
Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.
Agent drug coated balloon, Watchman product sales, and electrophysiology (EP) business unit growth offset Acurate discontinuation and tariff headwinds. CEO Michael Mahoney shouted out coronary therapies business and answered questions on CMS proposed Ambulatory Surgical Center codes.
The US FDA has launched the Regulatory Accelerator to expedite digital health product development. This includes resources like a Resource Index for Innovators, a Medical Device Software Guidance Navigator, and best practices for early meetings.
In his first 100 days as FDA commissioner, Martin Makary has gone from vocal critic to vocal supporter of the agency’s staff, calling them “phenomenal” and praising their dedication—even as morale remains shaken by recent layoffs and restructuring.